At Close: Dec 01, 2023
Sarepta Therapeutics (SRPT) Up 4.5% Since Last Earnings Report: Can It Continue?12:52pm, Friday, 01'st Dec 2023
Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?
5 Biotechnology Stocks to Buy for a Stable Portfolio in 202409:46am, Monday, 20'th Nov 2023
We have narrowed our search to five biotech stocks with strong potential for 2024. These are: LEGN, BGNE, GILD, EXAS, SRPT.
3 Stocks You'll Regret Not Buying Soon: November 202306:35am, Thursday, 16'th Nov 2023
The recent surge in official interest rates, the most substantial in 40 years, is anticipated to impact aggregate demand significantly. This could potentially result in a GDP reduction of approximatel
Here's Why Sarepta Therapeutics (SRPT) Is a Great 'Buy the Bottom' Stock Now11:18am, Monday, 13'th Nov 2023
Sarepta Therapeutics (SRPT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions cou
Insider Buys: Lumen, Air Products, Inari, Remitly and Sarepta07:52pm, Friday, 10'th Nov 2023
Hosted by Brian Sullivan, “Last Call” is a fast-paced, entertaining business show that explores the intersection of money, culture and policy. Tune in Monday through Friday at 7 p.m.
Is It Time to Buy the Nasdaq's 4 Worst-Performing October Stocks?09:03am, Wednesday, 08'th Nov 2023
Not all technology companies are the same. In fact, not all chipmakers are the same.
Sarepta Crashes 39% After Its Gene Therapy Flops Its Biggest-Ever Test01:59pm, Tuesday, 31'st Oct 2023
Sarepta Therapeutics' gene therapy, Elevidys, faces an uphill regulatory journey, analysts said Tuesday on mixed test results.
Why Is Sarepta Therapeutics (SRPT) Stock Down 47% Today?09:38am, Tuesday, 31'st Oct 2023
Sarepta Therapeutics (NASDAQ: SRPT ) stock is taking a beating on Tuesday after the biopharmaceutical company announced results from a Phase 3 clinical trial. That clinical trial covers the use of ELE
Sarepta shares slump as muscle disorder therapy fails to meet key trial goal08:50am, Tuesday, 31'st Oct 2023
Sarepta Therapeutics shares fell over 42% in premarket trading on Tuesday, after its gene therapy for a progressive muscle-wasting disorder failed to meet the main goal in a trial that was key to the
Sarepta Therapeutics Stock Halted After Unveiling Mixed Results For Its First Gene Therapy05:52pm, Monday, 30'th Oct 2023
Sarepta unveiled mixed results late Monday for a gene therapy that targets a muscle-wasting disease in boys. SRPT stock was halted.